Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
Abstract | OBJECTIVES: DESIGN: Phase 2, double-blind, placebo-controlled study (COVID- astegolimab-IL). SETTING: Hospitals. PATIENTS: INTERVENTIONS: Patients were randomized to receive IV astegolimab, efmarodocokin alfa, or placebo, plus standard of care. The primary endpoint was time to recovery, defined as time to a score of 1 or 2 on a 7-category ordinal scale by day 28. MEASUREMENTS AND MAIN RESULTS: The study randomized 396 patients. Median time to recovery was 11 days (hazard ratio [HR], 1.01 d; p = 0.93) and 10 days (HR, 1.15 d; p = 0.38) for astegolimab and efmarodocokin alfa, respectively, versus 10 days for placebo. Key secondary endpoints (improved recovery, mortality, or prevention of worsening) showed no treatment benefits. No new safety signals were observed and adverse events were similar across treatment arms. Biomarkers demonstrated that both drugs were pharmacologically active. CONCLUSIONS:
|
Authors | Michael Waters, James A McKinnell, Andre C Kalil, Greg S Martin, Timothy G Buchman, Wiebke Theess, Xiaoying Yang, Annemarie N Lekkerkerker, Tracy Staton, Carrie M Rosenberger, Rajita Pappu, Yehong Wang, Wenhui Zhang, Logan Brooks, Dorothy Cheung, Joshua Galanter, Hubert Chen, Divya Mohan, Melicent C Peck, COVID-astegolimab-interleukin (IL) (COVASTIL) Study Group |
Journal | Critical care medicine
(Crit Care Med)
Vol. 51
Issue 1
Pg. 103-116
(01 01 2023)
ISSN: 1530-0293 [Electronic] United States |
PMID | 36519984
(Publication Type: Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. |
Chemical References |
- astegolimab
- Interleukin-33
- Interleukin-1 Receptor-Like 1 Protein
|
Topics |
- Adult
- Humans
- COVID-19
- Interleukin-33
- SARS-CoV-2
- Interleukin-1 Receptor-Like 1 Protein
- Respiratory Distress Syndrome
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|